$59.00
Manufacturer: Netherlands
Hormone replacement therapy (HRT) to eliminate symptoms caused by estrogen deficiency in menopausal women no earlier than 6 months after the last menstruation. Prevention of osteoporosis in postmenopausal women with a high risk of fractures. Femoston should only be used in patients who are intolerant or have contraindications for the use of other medications for the prevention of osteoporosis (see the section “Features of use”). Experience in treating women over 65 yEars and Nose of age is limited.
Description
Femoston №28 Storage
estradiol tablet
active substance: estradiol;
1 tablet contains micronized estradiol hemihydrate, which is equivalent to estradiol 1 mg or 2 mg;
excipients: lactose monohydrate; hypromellose (HPMC 2910), corn starch, colloidal anhydrous silica, magnesium stearate;
film coating: Opadry® Y-1-7000 white (hypromellose (HPMC 2910), polyethylene glycol 400, titanium dioxide (E 171)) – for tablets containing 1 mg of estradiol;
Opadry® OY-6957 pink (hypromellose (HPMC 2910), polyethylene glycol 400, talc, iron oxide red (E 172), iron oxide black (E 172), iron oxide yellow (E 172), titanium dioxide (E 171)) – for tablets containing 2 mg of estradiol;
estradiol and dydrogesterone tablet
active substances: estradiol; dydrogesterone;
1 tablet contains micronized estradiol hemihydrate, which is equivalent to estradiol 1 mg or 2 mg; micronized dydrogesterone 10 mg;
excipients: lactose monohydrate; hypromellose (HPMC 2910), corn starch, colloidal anhydrous silica, magnesium stearate;
film coating: Opadry® II gray 85F27664 (polyethylene glycol 3350, talc (E 553b), polyvinyl alcohol, black iron oxide (E 172), titanium dioxide (E 171)) – for tablets containing 1 mg of estradiol and 10 mg of dydrogesterone;
Opadry® OY-02B22764 yellow (hypromellose (HPMC 2910), polyethylene glycol 400, talc, iron oxide yellow (E 172), titanium dioxide (E 171)) – for tablets containing 2 mg of estradiol and 10 mg of dydrogesterone.
Femoston №28 Dosage form
Film-coated tablets.
Basic physical and chemical properties:
tablet containing 1 mg of estradiol: round, biconvex, film-coated, white tablet marked “379” on one side; diameter 7 mm and a tablet weight of approximately 144 mg;
tablet containing 2 mg of estradiol: round, biconvex, film-coated, brick-red tablet marked “379” on one side; diameter 7 mm and a tablet weight of approximately 144 mg;
tablet containing 1 mg of estradiol and 10 mg of dydrogesterone: round, biconvex, film-coated, gray tablet marked “379” on one side; diameter 7 mm and a tablet weight of approximately 144 mg;
tablet containing 2 mg of estradiol and 10 mg of dydrogesterone: round, biconvex, film-coated, yellow tablet marked “379” on one side; diameter of 7 mm and a tablet weight of approximately 144 mg.
Femoston №28 Pharmacotherapeutic group
Drugs for the treatment of diseases of the genitourinary system and sex hormones. Combination drugs that contain progestogens and estrogens for sequential use. ATX code G03F B08.
Pharmacological properties. Pharmacodynamics. Estradiol
The active ingredient 17ß-estradiol is chemically and biologically similar to the natural female sex hormone estradiol. It replaces the loss of estrogen production in women during menopause and relieves menopausal symptoms.
Estrogens prevent bone loss after menopause or ovariectomy.
Dydrogesterone
Dydrogesterone is an active oral progestogen, the action of which is comparable to the action of progesterone administered parenterally.
Because estrogens stimulate endometrial growth, if no progestogen is used, they increase the risk of endometrial hyperplasia and carcinoma. The addition of a progestogen to therapy significantly reduces the risk of estrogen-induced in women with a preserved uterus.
Recent Reviews